Trial Profile
A Phase 1b/2 Study of GS-5829 in Combination With Fulvestrant or Exemestane in Subjects With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs GS 5829 (Primary) ; Exemestane; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 06 Aug 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 21 Sep 2018 Status changed from active, no longer recruiting to discontinued.